Health-Related Quality of Life in Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50–75 with Advanced Myelodysplastic Syndrome: BMT CTN 1102

The primary analysis of this Blood and Marrow Transplant Clinical Trials Network study showed the survival advantage associated with allogeneic hematopoietic cell transplantation in older adults with myelodysplastic syndromes did not come at the cost of worse quality of life.